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EDITORIAL_REVIEW
Antibody-coated bacteria in urinary tract infections
In 1974 we reported that a non-invasive fluorescent antibody
(FA) test is useful in establishing the anatomic site of infection
in the urinary tract [I]. The technique utilizes a simple and
direct immunofluorescence procedure to detect antibody-coat-
ed bacteria (ACB) in urine sediments of patients with urinary
tract infections. ACB are usually found in urine samples from
patients with kidney infections but not from patients with
uncomplicated bladder infections. This review focuses on the
efforts of our own laboratory and the work of other investiga-
tors in (1) evaluating the clinical application of the test for ACB
as a diagnostic aid, (2) determining the usefulness of the test in
defining populations for epidemiologic and therapeutic studies,
(3) ascertaining the prognostic usefulness of the test in following
the clinical course of the individual patient with persistent or
recurrent infections, and (4) defining the biological significance
of ACB in urine.
Localization of the anatomic site of infection
The reliability of the urine FA test as a means of localizing the
site of urinary tract infection has been established by comparing
it with direct localization studies [1—8]. Table I shows the
combined results of 8 groups of investigators who studied 310
adults comparing the FA test to ureteral catheterization and
bladder washout catheterization. There was agreement between
the results of the catheterization methods and the FA method in
258 of 311 studies (83%). For those patients with upper tract
infection, there was agreement in 154 of 175 studied (88%), and
for those infections confined to the bladder, there was agree-
ment in 104 of 136 studies (76%). The validity or accuracy of the
test is expressed in terms of sensitivity and specificity. Sensitiv-
ity is defined as the proportion of patients with renal bacteriuria
with positive PA tests for ACB; specificity indicates the propor-
tion of patients with bladder bacteriuria and negative FA tests
for ACB. The sensitivity of the test for ACB as established
collectively by this group of studies is 88% (range, 72 to 100%),
and the specificity is 76% (range, 50 to 100%). The predictive
value of associating a positive FA test for ACB with upper tract
infection is 83%; the predictive value of associating a negative
FA test for ACB with bladder bacteriuria is 83%.
Discrepancies in the ACB test compared to bladder wash-out
There was disagreement between the FA test results and the
results of direct localizations in 53 out of 311 combined studies
(17%) reported by the 8 investigators (Table 1). While limita-
tions in the accuracy of the bladder-washout test may be a
consideration [9], analysis of the reasons for "false" negative
and "false" positive results has been a useful stimulus in our
understanding of factors influencing the immune response of the
urinary tract. Interobserver variability may account for some
differences, although these are probably minor. Schaberg et al
studied interobserver variability and found agreement among 3
independent observers in 88% (223 of 253) of the specimens on
1
the first reading [10]. The percent agreement increased to 96
after the second reading.
Variation in methodology may explain some of the discrepan-
cies among the 8 studies [11]. The methods of interpreting PA
tests as positive differed among investigators. Thomas et al [1]
and Reidasch et al [7] interpreted a test as positive when greater
than or equal to 20% or 25% of the organisms in each micro-
scopic field fluoresced. Other investigators used much smaller
numbers of fluorescing organisms to indicate a positive test. For
example, Jones, Smith, and Sanford [2] used more than or equal
to 2 fluorescing organisms in a total of 200 fields, and Harding
[8] used as many as 5 or more fluorescing organisms in a 5-mm
screening of each slide. Because the cutoff point for a positive
test varied, results can be expected to vary. Thus, the over-
interpretation of small numbers of fluorescing bacteria may
have accounted for the higher numbers of false-positive FA test
results for patients with lower tract infections (24%) than false-
negative results for patients with upper tract infections (12%).
However, methodology cannot be the only reason for these
differences. Even though Thomas et al and Reidasch et al used
similar criteria for determining a positive test, their overall
results were different. Thomas et a! reported a 100% correlation
between the PA method and direct localization studies; Rei-
dasch reported a 72% correlation for patients with upper tract
infection and a 70% correlation for patients with bladder
infection. These variations are more likely explained by the
patient populations studied and the likelihood of false-negative
and false-positive test results among certain groups of patients,
as we will consider.
False-negative test results for ACB
The possibility of false-negative results must be considered
for patients with upper trart infections (Table 2). It is well
known that patients with aute pyelonephritis may not have
ACB in their urine samples [2, 12, 13]. We reported that 20% of
the obstetrical patients with acute pyelonephritis in our study
population had negative results. We concluded that the duration
of exposure was too brief; the patients developed acute symp-
toms and were treated before an immune response detectable
by the FA test had occurred [12]. The role of duration of
infection in the development of antibody-coating was supported
by a multicenter study which demonstrated that the occurrence
of positive ACB tests correlated with the duration of symptoms.
The differences in the accessibility of medical care and the
tolerance of symptomatic infection resulting in certain patient
populations delaying medical care were suggested as explana-
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Table 1. Localization of the anatomic site of urinary tract infection: Results of the fluorescent antibody test in adult patients for detection of
antibody-coated bacteria in urine sediment compared to results of ureteral or bladder washout catheterization
Reference Direct No. upper No. lower
no. of No. of localization No. pos. tract No. neg. tract
group studied patients method FA tests infections FA tests infections
1" 28 BW 27/27 (100%) 1/1 (100%)
Uc
2 26 BW 17/18 (94) 8/8 (100)
3 26 BW 18/18 (100) 8/8 (100)
4 9 BW 5/5 (100) 2/4 (50)
5 5 UC 4/4 (100) 2/2 (100)
6 31 UC 16/16 (100) 10/15 (67)
7 134 UC 36/50 (72) 59/84 (70)
8 51 BW 31/37 (84) 14/14 (100)
Total 310 154/175 (88%) 104/136 (76%)
Abbreviations used are defined as: BW, bladder washout catheterization; FA, fluorescent antibody; UC, ureteral catheterization.
b Nine patients from Refs. I and 19 previously unreported patients.
Table 2. Reasons for false-negative and false-positive test results for antibody-coated bacteria (ACB)
in patients with upper and lower tract infections
Upper tract infections Lower tract infections
False-negative results References cited False-positive results References cited
Acute pyelonephritis 2, 12, 13 Urine contaminated by ACB 18, 19
Mucoid coating on bacterial 16 from vaginal or fecal flora
cell surface Prostatitis 1, 20, 21
Insufficient amount of bacteria- 17 Proteinuria 22, 23, 24
specific antibody to result Hemorrhagic cystitis 7, 25
in detectable ACB Bladder tumors 7, 26
Bladder wall lesions 7
Heal conduit 28, 29
Residual cross-reacting antibody 30
from previous kidney infection
tions for the percentages of positive FA tests ranging from 8 to
63% among the study populations at the 3 participating institu-
tions [14]. Studies of experimental pyelonephritis in rabbits
showed that it may take from 8 to 21 days before ACB appear in
the urine after initiation of infection [15].
Another explanation for the occurrence of false-negative
results is the inability of the antibody to combine with the
infecting bacteria, despite the development of a specific im-
mune response. In a study by Marrie et a! [16], false-negative
results occurred because of a mucoid coating of extracellular
polysaccharide on a strain of Pseudomonas aeruginosa that
blocked antibody attachment. Even though an antibacterial
antibody was present, it could not reach the masked surface
antigens on the bacterial cell wall.
We have observed that a negative ACB test may occur in the
presence of elevated, urinary, bacteria-specific antibody levels
as determined by radioimmunoassay (RIA) because the un-
bound, urinary antibody, although elevated, is not present in
sufficient quantity to result in a detectable antibody-coating of
the invading bacteria by the less sensitive FA method [17].
Results from our studies showed that 7 out of 32 patients (22%)
with acute pyelonephritis and 19 of 59 patients (32%) with
cystitis had negative tests for ACB in the presence of elevated
amounts of bacteria-specific antibody in the urine as deter-
mined by RIA; there was no significant difference between the
mean RIA binding ratios of antibody activity for these 2 groups
of patients (5.8 and 5.6, respectively). However, there was a
significant difference between the mean binding ratios of these 2
groups compared to patients with acute pyelonephritis who
have positive tests for ACB and elevated RIA binding ratios
(mean binding ratio, 12).
False-positive test results for ACB
False-positive FA test results occurred in 32 out of 136 direct
localization studies (24%) for patients with lower tract infec-
tions (Table 1). Over-interpretation of small numbers of fluor-
escing organisms may account for some of these discrepancies,
particularly in one study [6] which reported 5 of 15 patients
(33%) with lower tract infections who had ACB in their urine
samples. The criteria employed for a positive test was more
than or equal to 1% fluorescing organisms. The investigators
tested clean-catch, midstream, and voided urine samples by FA
rather than the catheterized specimens taken during the local-
ization procedure. It is possible that small numbers of ACB
from the vaginal vestibule flora may have contaminated the
urine samples. We found that ACB are frequently present in the
vaginal vestibule flora of patients without urinary tract infec-
tions. Other investigators have also made this observation [18,
19]. A false-positive test may be due to contamination of voided
urine with ACB and yeast from the vagina and vaginal vesti-
bule. The possibility of such contamination becomes a major
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problem if the criterion for a positive FA test is a rare or
occasional fluorescing organism.
Factors other than methodology must be considered in inter-
preting results. For example, positive FA test results may occur
from male patients with prostatitis (Table 2). We observed ACB
in urine samples from 4 of 5 patients with prostatitis [1]. Jones
confirmed this finding in a patient with chronic prostatitis and
demonstrated the specificity of the antibody for the infecting
Escherichia co/i. He employed an indirect immunofluorescence
technique using prostatic fluids from the reference patient and a
second patient with chronic prostatitis. Antibody titers were
elevated in the prostatic fluid of both patients but only to their
individual infecting organisms [20]. Riedasch et al examined the
ejaculates of 51 patients with prostatic symptoms and found
ACB in 17 of 25 with more than or equal to 100,000 bacterial
colonies per ml of ejaculate; 8 of 26 with fewer cultured
organisms also had ACB [21]. ACB were present in all 5
patients with epididymitis. ACB could not be demonstrated in
ejaculates from 14 normal controls, although 3 contained bacte-
ria. The specificity of the antibody coating and the occurrence
of ACB in the 8 patients whose ejaculates contained less than
100,000 organisms per ml suggest the usefulness of the method
in the diagnosis of bacterial prostatitis. However, the absence
of ACB does not exclude a diagnosis of prostatitis. A clinical
and laboratory study of patients with well-documented chronic
prostatitis whose ejaculates are ACB-negative would be of
interest to determine the role of host and pathogen factors
responsible for the absence of antibody coating.
Proteinuria may be associated with positive FA tests. Thom-
as, Forland, and Shelokov [22] studied the relationship of ACB,
proteinuria, and immunoglobulinuria in 24 patients with urinary
infections. Each of the 12 patients with cystitis and negative
ACB tests and the 12 patients with chronic pyelonephritis and
positive ACB tests had proteinuria. These patients were select-
ed for study because of their underlying noninfectious renal
disease. Results showed that a positive ACB test was not
dependent on the occurrence of elevated total protein, IgG,
IgA, or 1gM in the urine. Conversely, uncoated bacteria were
found in urine samples from patients with cystitis even in the
presence of elevated levels of total urinary immunoglobulins
and protein. These studies indicate the importance of antibody
specificity for the development of ACB. Elevated immunoglob-
ulins may be present; however, if the specificity is for an
antigen other than the surface antigens of the bacteria causing
the infection or closely related bacteria, the FA test will be
negative. In subsequent studies, Thomas, Forland, and Shelo-
kov [23] used indirect immunofluorescence to detect the anti-
body against common urinary pathogens in 7 urine specimens
from 5 patients with proteinuria and negative cultures. Each
urine sample was tested against 7 different subcultured bacteria
isolated from other patients with urinary tract infections; 9 of 49
tests (18%) gave weak fluorescence reactions. Five of the
reactions were from a single patient with diabetic glomerulo-
sclerosis whose serum contained high titers of a circulating
antibody against K. pneumoniae, one of the test organisms.
These results suggested a probable previous infection. Braude
and Block [24] demonstrated urinary IgG antibodies in 11 of 18
tests (61%) in specimens from 3 noninfected proteinuric pa-
tients. The antibody was directed against 6 bacterial urinary
pathogens and in one instance against Candida a/bicans. The
authors suggested that bacteria or fungi contaminating the urine
of uninfected proteinuric patients may give false-positive stud-
ies.
False-positive ACB tests have been associated with hemor-
rhagic cystitis. Rumans and Vosti [25] found that 6 out of 75
patients (8%) with a clinical diagnosis of lower tract infection
had positive FA tests for ACB; 4 of these 6 patients with false-
positive results had hemorrhagic cystitis. Riedasch et al [7]
found that each of 6 patients with severe hemorrhagic cystitis
had ACB in their urine samples. The diagnoses were verified by
cystoscopic examination which revealed typical mucosal hem-
orrhage but no other bladder wall lesions. We have found that
not all patients with urinary tract infection and gross hematuria
have ACB in their urine samples; 9 of 16 samples from patients
with gross hematuria (56%) did not contain ACB. In these
instances, it is likely that an antibody was not present or
specific for the invading bacteria. Positive FA tests with
hemorrhagic cystitis are probably due to passage into the urine
of a circulating antibody with specificity for the infecting
microorganism. In some cases there may be hematuria resulting
from bladder wall lesions with tissue invasion and local synthe-
sis of antibacterial antibody.
Bladder tumors and bladder wall lesions may be associated
with positive FA tests for ACB. Even though their episode of
urinary infection appeared clinically to be a lower tract infec-
tion, 14 of 19 patients (74%), observed by Forsum [9] and with
carcinoma of the bladder, prostate, or kidney, had positive
ACB tests. Riedasch et al [7] found that practically all the
patients in their study with lower urinary tract infections
(confirmed by ureteral catheterization) who had bladder tu-
mors, bladder stones, or bladder wall lesions had positive ACB
tests. Thus, the human bladder is capable of mounting an
immune response in lower tract infections, particularly if the
mucosal barrier is broken via stones, tumors, or other lesions.
These breaks in the mucosa likely allow the invading microbe a
passageway into the bladder wall tissue. Without these lesions,
the bacteria usually do not gain entrance into the deeper tissue
and therefore, usually do not elicit a local immune response.
Experimental animal studies by Hand, Smith, and Sanford [27]
had earlier demonstrated antibody production with experimen-
tal cystitis in rabbits. The lesion induced in this animal model
was a more severe lesion than that typically observed with
uncomplicated bladder infections of humans. The lesion in-
volved deep wall tissue and was associated with a local immune
response.
False-positive FA tests may be associated with ileal conduit
specimens. Woodside et al [28] found ACB to be present in
specimens from 9 patients with significant bacteriuria; urine
samples were collected by a double catheter technique from an
ileal conduit urinary diversion. Each of the patients was asymp-
tomatic, although 3 did have abnormal pyelographic features
indicating pyelonephritis. From these studies it appears that a
positive ACB test alone does not necessarily indicate a paren-
chymal infection in patients with bacteriuria associated with
ileal conduits. Specific determination of IgG or IgA as the
coating immunoglobulin did not assist in the differentiation,
although IgA was more common in patients with conduits than
nephrostomy drainage. In a later study, these investigators
observed that IgA was more often present and in greater
amounts than other immunoglobulins in urine samples from
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both infected and noninfected patients with conduits as com-
pared to specimens from patients with nephrostomy drainage
[29]. These results suggested to the authors that the ileum may
be the site of IgA production and that IgG may be the
predominant immunoglobulin produced from renal parenchy-
mal infection. They suggest that a rise in the IgG:IgA ratio may
indicate pyelonephritis in the patient with an ileal conduit. They
made this observation in the study of only one patient. It would
be of interest to study a group of patients to determine whether
or not this hypothesis is valid.
Thomas et al 1301 have shown by indirect immunofluores-
cence that a free, antibacterial antibody in the urine samples of
patients with urinary infection may react with bacteria other
than the one causing the infection. The weak fluorescence
observed with heterologous bacteria is probably due to the
cross reactivity of urinary antibody with various antigens.
Studies showed that a free antibody may be present in the urine
for as long as 4 months, possibly longer after the infection
subsides. This could cause false-positive ACB tests, as an
antibody from a previous kidney infection may coat closely
related bacteria of a newly established bladder infection.
Correlation with radiologic findings
Our initial observations concerning the significance of anti-
body-coating were based in part on correlations with indirect
localization [1]. Some patients were selected for independent
immunologic study because of our confidence in localization
based on the clinical and laboratory findings which included the
presence or absence of renal radiologic and functional changes.
Subsequent studies have addressed independently the question
of whether or not the presence of antibody-coating correlates
with radiologic evidence of upper tract disease. In a study of
children, Kwasnik, Klauber, and Tilton [31] found 26 of 27
patients with radiologic indications of pyelonephritis, including
thinning of the renal parenchyma, visible scars, calyceal club-
bing, hydronephrosis, and stone formation, had ACB. Forty-
three of 49 patients with normal radiologic studies were ACB-
negative, while 6 had ACB. Harding et al [8] found 9 of 11
patients with abnormal pyelograms had ACB. All 11 exhibited
upper tract localization during a bladder-washout study; 7 were
asymptomatic.
Pujol et al found abnormalities on intravenous pyelography or
voiding cystourethrograms in 35 of 36 patients with ACB [321.
Radiological studies were negative in all but 1 of 20 patients
with negative FA tests; the I had residual bladder urine.
Canarelli et a! found antibody-coating present in all 6 patients
with radiologic abnormalities [331. Bladder-washout was also
positive in all. Three of 4 with normal intravenous pyelograms
and positive bladder-washout studies had antibody-coating; the
fourth exhibited acute pyelonephritis. In a group of 47 patients
with a diagnosis of chronic pyelonephritis, Boisivon, Guibert,
and Acar reported 45 had ACB and 41 had abnormal intrave-
nous pyelograms [34]. Clearly the presence of antibody-coating
must alert the clinician to the possibility of an underlying
anatomical genitourinary abnormality.
Bladder catheterization
Gonick et al [35] examined the incidence and site of urinary
infections in hospitalized patients with indwelling catheter
drainage. Upon examination of all patients in the hospital with
indwelling catheters on the initial day of the study, they found
27 of 72 patients (39%) had positive cultures. Six (22%) of the
infections were with antibody-coated organisms. They discov-
ered that both the occurrence of significant bacteriuria and
antibody-coating correlated with the duration of catheteriza-
tion. With the catheter in place 1 day or less, 2 cultures were
positive (13%) and with 4 or more days, 17 cultures (55%) were
positive. With 3 or less days of catheterization, 1 patient had
antibody-coated organisms (2%); with 4 or more days, 5 pa-
tients (16%) had ACB. When reviewing patients with an initial
infection, 8 of 10 continued to have significant bacteriuria. A
limitation of this study was the use of fluorescein-conjugated,
anti-human IgG for the demonstration of antibody-coating; the
number of infecting organisms with antibody-coating might
have been significantly higher if polyvalent, anti-human, gam-
ma globulin-conjugate had been used, making it possible to also
detect the IgA coating [36]. Gurtler [37] found ACB in 20 of 25
women with indwelling bladder catheters. Five of 9 studied
further had positive bladder-washout tests, and 7 had ACB. The
author suggested indwelling catheters may be responsible for
false-positive tests, Further studies of catheterized patients are
needed comparing ACB with other localization techniques.
These should include serial longitudinal ACB studies with
determination of specific immunoglobulins in newly catheter-
ized patients.
Pregnancy
Thomas et a! [12] demonstrated the application of urinary
ACB testing for differentiating acute pyelonephritis from cysti-
tis in pregnancy. ACB were present in urine samples from 12 of
15 patients with acute pyelonephritis. ACB were not observed
in urine samples from 13 patients with cystitis. The acute
development of symptomatic, upper tract involvement and
prompt treatment were postulated to account for the lack of
antibody-coating in 20% of the patients with acute pyelonephri-
tis.
In a prospective study, Harris, Thomas, and Shelokov [38]
found asymptomatic bacteriuria in 70 (5%) of 1400 pregnant
women. ACB were present in specimens from half (35) of the
patients. A small but significant elevation in serum creatinine
was found in patients whose infections were associated with
ACB. Creatinine clearance was less than 90 mI/mm in 15 of 26
(58%) ACB-associated infections, in only I of 29 ACB-negative
infections, and in 1 control patient without infection. Intrauter-
ine growth retardation, defined as infant weight below the 10th
percentile of "normal" weight for the gestational age, occurred
in 4 of 53 (7.5%) mothers with asymptomatic bacteriuria as
contrasted to 21 of 1330 (1.6%) with negative cultures. The 4
mothers each had a positive test for ACB. Intrauterine growth
retardation was found in 4 of 27 (15%) infants born to mothers
with positive FA tests. The authors suggest the finding of a
positive FA test in pregnancy selects the patient who requires
renal function evaluation and a high index of suspicion regard-
ing development of intrauterine growth retardation,
Transplantation
Our laboratory initially reported the occurrence of ACB in a
patient who had a renal transplant and had been maintained on
conventional corticosteroid and azathioprine therapy. This pa-
tient developed a urinary tract infection [39]. Upper tract
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localization was confirmed for Proteus mirabilis by the bladder-
washout technique as well as a sharp rise in serum antibody
titer as measured by indirect immunofluorescence. Keren et a!
observed 80 renal transplant patients prospectively for 6
months [40]. Four patients with either the clinical picture or
histopathologic findings of pyelonephritis had ACB. Twenty-
three patients with bacteriuria without clinical or histopatholog-
ic evidence of pyelonephritis had FA-negative studies; howev-
er, direct localization studies were not performed, and the
authors drew no conclusions about the significance of a nega-
tive result in the immunosuppressed patient. Riedasch Ct al also
confirmed the ability of patients with renal transplants to
demonstrate an immune response to urinary tract infection [41].
Of 24 patients observed for 6 months, beginning 8 weeks after
transplantation, 13 developed urinary tract infections. ACB
were demonstrable in 7 of the 13. Conversion to a positive test
was associated with a pyelostomy in 1 patient. IgG was present
on bacteria from all 7 patients and associated with IgA in 6.
Urinary tract infection in children
A particularly puzzling aspect of clinical experience with
ACB as a tool for localization has been the discrepancy
between ACB localization and direct [42, 43, 44] as well as
indirect localization techniques [45, 46] in observations of
children found by a number of investigators [18, 31].
The possible role of collection problems was suggested by
Montplaisir, Courteau, and Roche [19]. Difficulty obtaining
clean-voided specimens, particularly in small girls, could result
in contamination with small numbers of ACB of perineal origin.
This difficulty would not account for the discrepancies in
studies such as those made by Hellerstein et al, citing the use of
catheterized bladder washout specimens [42]. Age correlation
within the pediatric range has not been observed with the false-
positive or false-negative ACB results. The possibility of need
for a longer, latent period for development of ACB because of a
lesser likelihood of previous exposure to the organisms in
childhood remains a consideration. Studies by other groups
suggest an impaired immunologic response with urinary tract
infections in infancy as compared to older children [47]. A
direct affect of age could be explored in a rat model comparing
young and mature animals.
During an observation of 55 school girls, Silverberg, Jackson,
and Bryan found ACB in 1 of 5 children with calyceal scarring
and 1 of 2 with mild ureterovesical reflux [45]. Evidence of
pyelonephritic scarring was present in only 1 of 5 with ACB and
1 of 3 was found to have reflux. All patients were asymptomat-
ic. The authors suggested the kidneys may produce less tissue
response during the asymptomatic infection. This suggestion is
analogous to the low C-reactive protein, ESR values, and serum
antibody titers observed by Lindberg et al [48] in studies of
children with asymptomatic infections.
Treatment
Consensus concerning optimal dosage and duration of antimi-
crobial therapy remains to be achieved in the area of urinary
tract infections. Increasing clinical experience suggests the
traditional 10- to 14-day course of treatment is unnecessary for
uncomplicated cystitis-urethritis [49, 50, 51]. Questions also
remain as to whether or not prolonging treatment beyond 10 to
14 days is useful in the management of renal parenchymal
infection, particularly because a number of studies in women
indicate recurrence in upper tract infection is most often related
to reinfection rather than relapse [52, 531. Consequently, a
simple, easily repeatable, and non-invasive localization tech-
nique should help resolve some of these issues.
In a study combining children and adults, Kulasinghe, Cush-
ing, and Reed observed 2 relapses in 29 ACB-negative infec-
tions treated for 14 days or less [5]. In contrast the 4 patients
with ACB-positive infections treated for 14 days or less re-
lapsed within 2 months. Nine patients with ACB-positive
infections treated for 28 days or more had no relapses within 2
months; 3 later had reinfections.
Fang, Tolkoff-Rubin, and Rubin [50] found no difference in
the response of 43 patients with ACB-negative infections treat-
ed with a single dose of 3 g amoxicillin or 1 g per 24 hours for 10
days. The former group of 22 patients and the latter of 21
patients each had 2 reinfections by 4 weeks. In contrast, of 18
patients with ACB-positive infections treated for 10 days with 1
g amoxicillin per 24 hours, 9 had relapses at 1 week; 3 of those 9
subsequently relapsed after an additional 14 to 21 days of
treatment. A 50% relapse rate within a week is considerably
higher than most clinical experiences and suggests a group of
patients with complicated upper tract infection. In a subsequent
cooperative study in which the same group participated, similar
responses with ACB-negative infections were seen with a single
dose of amoxicillin (90%) compared to 10-day courses of
trimethoprim-sulfamethoxazole (100%) or ampicillin (96%) [14].
Ludwig et al have also reported on the efficacy of either single-
dose sulfisoxazole or trimethoprim-sulfamethoxazole in the
treatment of ACB-negative infections [51].
In our ongoing study of 50 diabetic women with urinary tract
infections, we have found no advantage of 6 weeks of treatment
with trimethoprim-sulfamethoxazole over 2 weeks of therapy in
ACB-positive infections in regard to the frequency of recur-
rence or the bacteriuria-free interval prior to recurrence [54].
Approximately 75% of recurrences in both groups were reinfec-
tion—recurrences with a different serogroup of E. coli or
species of bacteria. Similar findings were reported by Rubin et
al [14]: Nineteen of 26 patients with ACB-positive infections
were cured and did not exhibit a statistical difference between 2
or 6 weeks of amoxicillin therapy [55].
Two recent studies indicate the efficacy of long-term antibac-
terial therapy in men with recurrent urinary tract infections
associated with ACB [56, 57]. Gleckman, Crowley, and Natsios
[56] demonstrated fewer relapses in men treated with trimetho-
prim-sulfamethoxazole for 6 weeks (3 men out of 19) as
compared to 2 weeks (10 men out of 19); 3 reinfections occurred
in each group. In a collaborative study of similar design, 12
recurrences followed 10-day courses in 15 patients, and 6 in 15
patients treated for 12 weeks [57]. More than half the men had
evidence of prostatic involvement; most recurrences were
asymptomatic relapses. The latter authors suggested that the
ACB test selected those men most likely to have a recurrence
after a 10-day course of therapy.
Conclusions
The major clinical usefulness of a positive test for ACB is the
indication to the physician that the problem is more than a
simple lower tract inlection. Either kidney or prostatic involve-
6 Thomas and For/and
ment is present, or an "invasive" bladder infection has oc-
curred related to the presence of stones, malignancy, recent
surgery, or hemorrhagic cystitis. A negative ACB test in the
absence of a clinical picture of acute pyelonephritis provides
reasonable assurance that renal, prostatic, or invasive bladder
infection is absent. The therapeutic guidelines predicated by
these findings suggest that the patient with a negative ACB test
will respond well to a short course of therapy, even of one to
three days' duration. The male with ACB and recurrent infec-
tion appears to have the least likelihood of prompt relapse if
therapy is prolonged for 6 to 12 weeks, probably because of
chronic prostatic involvement. The limited studies available do
not support maintaining treatment in women with ACB beyond
10 to 14 days because of the rapidity of recurrences after
therapy; however, it is premature to set firm therapeutic
guidelines and additional studies are necessary, particularly in a
population with well-defined, relapse infections.
Clinical areas requiring further definition include the unex-
plained lack of correlation of ACB with bladder washout
studies in the pediatric population. Are age, duration of infec-
tion, or the number of previous recurrences playing roles in
these discordant findings? Further correlations with the out-
come of pregnancy, as well as studies on the frequency,
sequence of immunoglobulin appearance, and significance of
ACB in the catheterized patient are necessary. Finally, funda-
mental questions remain regarding ACB, the pathophysiology
of urinary tract infection and host-organism interrelationships.
Are the presence of immunoglobulins in the perineal area
protective to the host [581 and also protective to the invading
organism in the unique environment of the kidney [59J? The
persistence of renal infection over periods of years despite a
sustained immunologic response as strikingly demonstrated by
ACB continues to challenge investigators working in the area of
host-organism interrelationships.
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